Stock SGBI SANGUI BIOTECH INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sangui Biotech International, Inc. OTC Markets

Equities

SGBI

US80105B1017

Delayed OTC Markets
Other stock markets
 02:24:30 2024-01-17 pm EST 		5-day change 1st Jan Change
0.0015 USD +25.00% Intraday chart for Sangui Biotech International, Inc. -.--% -48.28%
May. 15 Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Feb. 15 Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Sangui BioTech International Inc.: Significant increase in sales in the first three quarters of the year - Further reduction of the operating loss
EQ
Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
CI
Sangui BioTech International Inc.: Significant increase in sales in the first half of the year - Further reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
CI
Sangui BioTech International Inc.: - Sales of USD 41,029 in first quarter - For the first time, positive quarterly result in the company's history
EQ
SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022
CI
SANGUI BIOTECH INTERNATIONAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
Sangui BioTech International Inc.: Increase in sales in the first quarter of 121% - Highest quarterly sales in the company's history
EQ
Sangui BioTech International Inc.: Sales of USD 69,190 in fiscal year 2022 - Reduction of the operating loss
EQ
SANGUI BIOTECH INTERNATIONAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022
CI
Sangui Biotech International, Inc. Auditor Raises 'Going Concern' Doubt
CI
Sangui Biotech International : Annual Statement of Changes in Beneficial Ownership - Form 5
PU
Sangui Biotech International : Annual Statement of Changes in Beneficial Ownership - Form 5
PU
Sangui BioTech International Inc.: - Increase in sales in the first nine months of the year - Further reduction of the operating loss
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SBH Stock
  4. SGBI Stock
  5. News Sangui Biotech International, Inc.